Back to Browse Journals » Journal of Inflammation Research » Volume 3

Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis

Authors Slobodan M Jankovic

Published Date March 2010 Volume 2010:3 Pages 25—31

DOI http://dx.doi.org/10.2147/JIR.S9480

Published 16 March 2010

Slobodan M Jankovic

Pharmacology Department, Medical Faculty, University of Kragujevac, Kragujevac, Serbia

Abstract: Multiple sclerosis (MS) is chronic inflammatory and demyelinating disease with either a progressive (10%–15%) or relapsing-remitting (85%–90%) course. The pathological hallmarks of MS are lesions of both white and grey matter in the central nervous system. The onset of the disease is usually around 30 years of age. The patients experience an acute focal neurologic dysfunction which is not characteristic, followed by partial or complete recovery. Acute episodes of neurologic dysfunction with diverse signs and symptoms will then recur throughout the life of a patient, with periods of partial or complete remission and clinical stability in between. Currently, there are several therapeutic options for MS with disease-modifying properties. Immunomodulatory therapy with interferon beta-1b (IFN-β1b) or -1a, glatiramer and natalizumab shows similar efficacy; in a resistant or intolerant patient, the most recently approved therapeutic option is mitoxantrone. IFN-β1b in patients with MS binds to specific receptors on surface of immune cells, changing the expression of several genes and leading to a decrease in quantity of cell-associated adhesion molecules, inhibition of major histocompatibility complex class II expression and reduction in inflammatory cells migration into the central nervous system. After 2 years of treatment, IFN-β1b reduces the risk of development of clinically defined MS from 45% (with placebo) to 28% (with IFN-β1b). It also reduces relapses for 34% (1.31 exacerbations annually with placebo and 0.9 with higher dose of IFN-β1b) and makes 31% more patients relapse-free. In secondary-progressive disease annual rate of progression is 3% lower with IFN-β1b. In recommended doses IFN-β1b causes the following frequent adverse effects: injection site reactions (redness, discoloration, inflammation, pain, necrosis and non-specific reactions), insomnia, influenza-like syndrome, asthenia, headache, myalgia, hypoesthesia, nausea, paresthesia, myasthenia, chills and depression. Efficacy of IFN-β1b in  relapsing-remitting MS is higher than that of IFN-β1a, and similar to the efficacy of glatiramer acetate. These facts promote IFN-β1b as one of the most important drugs in the spectrum of immunological therapies for this debilitating disease.
Keywords: multiple sclerosis, interferon beta 1b, mechanism of action, efficacy, safety

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Therapeutic antitumor efficacy of tumor-derived autophagosome (DRibble) vaccine on head and neck cancer

Su H, Luo Q, Xie H, Huang XF, Ni YH, Mou YB, Hu QG

International Journal of Nanomedicine 2015, 10:1921-1930

Published Date: 10 March 2015

Nanostructured systems containing babassu (Orbignya speciosa) oil as a potential alternative therapy for benign prostatic hyperplasia

de Sousa VP, Crean J, Borges VRA, Rodrigues CR, Tajber L, Boylan F, Cabral LM

International Journal of Nanomedicine 2013, 8:3129-3139

Published Date: 15 August 2013

Surgical outcomes in phacoemulsification after application of a risk stratification system

Tsinopoulos IT, Lamprogiannis LP, Tsaousis KT, Mataftsi A, Symeonidis C, Chalvatzis NT, Dimitrakos SA

Clinical Ophthalmology 2013, 7:895-899

Published Date: 16 May 2013

Lower extremity venous thrombosis in patients younger than 50 years of age

Kreidy R, Salameh P, Waked M

Vascular Health and Risk Management 2012, 8:161-167

Published Date: 13 March 2012

Study of optimal exposure windows using 320-Detector rows dynamic volume CT

Gang Sun, Min Li, Li Li, et al

Reports in Medical Imaging 2010, 3:115-122

Published Date: 6 December 2010

Pretreatment with intraluminal rapamycin nanoparticle perfusion inhibits neointimal hyperplasia in a rabbit vein graft model

Kai Liu, Guangqing Cao, Xiquan Zhang, et al

International Journal of Nanomedicine 2010, 5:853-860

Published Date: 11 October 2010

Detection of label-free cancer biomarkers using nickel nanoislands and quartz crystal microbalance

Adrián Martínez-Rivas, Patrick Chinestra, Gilles Favre, et al

International Journal of Nanomedicine 2010, 5:661-668

Published Date: 6 September 2010

Magnetic nanoformulation of azidothymidine 5’-triphosphate for targeted delivery across the blood–brain barrier

Zainulabedin M Saiyed, Nimisha H Gandhi, Madhavan PN Nair

International Journal of Nanomedicine 2010, 5:157-166

Published Date: 11 March 2010

Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk

Ajikumar V Aryangat, John E Gerich

Vascular Health and Risk Management 2010, 6:145-155

Published Date: 9 March 2010

Pleiotropic effects of statins in atrial fibrillation patients: the evidence

Hadi AR Hadi, Wael Al Mahmeed, Jassim Al Suwaidi, Samer Ellahham

Vascular Health and Risk Management 2009, 5:533-551

Published Date: 17 June 2009